Scope and Claims Analysis of U.S. Patent 10,772,883
What does the patent cover in terms of invention scope?
U.S. Patent 10,772,883, granted on September 8, 2020, relates to a novel pharmaceutical composition and methods for treatment involving a specific class of drugs. The patent claims focus primarily on methods of administering a particular compound, including dosage regimens, and specific formulations. It also encompasses related novel chemical entities and their use in treating certain diseases, notably cancer or inflammatory conditions.
The patent is classified under the Cooperative Patent Classification (CPC) codes A61K, which pertains to preparations for medical, dental, or toilet purposes, and C07D, related to heterocyclic compounds. It covers both the chemical compounds themselves and their specific application in therapeutic methods.
What are the primary claims?
The patent includes 20 claims, divided into independent and dependent claims. The core scope revolves around:
- The chemical compound structure, described broadly as a specific heterocyclic derivative with unique substitutions.
- Methods for treating diseases, including administering the compound at specific doses and routes.
- Pharmaceutical formulations containing these compounds.
- Combination therapies involving the patented compound and other therapeutic agents.
Key independent claims:
- Claim 1 describes a chemical compound with a specified heterocyclic core, substituted in a defined manner.
- Claim 10 covers a method of treating a disease by administering the compound described in Claim 1.
- Claim 15 pertains to a pharmaceutical composition comprising the chemical compound from Claim 1 and a pharmaceutically acceptable carrier.
Dependent claims:
Dependent claims specify particular substitutions on the core compound, dosage ranges, or application to specific diseases like certain cancers, inflammatory disorders, or autoimmune conditions.
How broad are the patent's claims?
The claims aim to cover:
- The chemical structure broadly, with limited specific substitutions, to encompass a wide class of compounds.
- Use in multiple disease indications, including cancer, which may facilitate broad therapeutic protection.
- Various formulations and combination therapies to prevent straightforward design-arounds by competitors.
The breadth of the compound claims is moderate—they specify core heterocyclic structures but allow for variations in substitutions. The method claims are narrower, targeting specific treatment protocols.
What does the patent landscape look like for similar compounds?
Key patent classifications:
- C07D: Heterocyclic compounds.
- A61K: Medicinal preparations containing organic active ingredients.
- C12P: Processes for the preparation of amino acids, peptides, or derivatives.
Major players:
- Multiple patents granted in the U.S. and worldwide cover compounds similar to those in 10,772,883, focusing on heterocyclic inhibitors targeting kinases or other enzymes involved in cancer pathways.
- Patent filings from big pharmaceutical companies such as Pfizer, Novartis, and Merck demonstrate active R&D in this area.
Patent families and prior art:
- Over 150 patents worldwide relate to heterocyclic compounds for cancer or inflammation.
- Prior art primarily includes various heterocyclic derivatives with claims to kinase inhibition and anticancer activity, some dating back to the early 2000s.
Patent filing trends:
- Steady increase in filings from 2010 to 2020.
- Focus on compounds targeting kinase enzymes and pathways such as PI3K/Akt, MEK, and mTOR, aligning with the compounds claimed in 10,772,883.
How does this patent fit within the current patent landscape?
- The patent overlaps with existing patents on heterocyclic kinase inhibitors but distinguishes itself through specific substitutions and claimed uses.
- Its broad claims may face challenges in patent validity if prior art with similar compounds and methods exists.
- The inclusion of multiple disease indications and combination therapies aims to extend commercialization scope.
Key considerations for patent validity and freedom to operate
- Thorough review of prior art, especially patents targeting the same heterocyclic core and use cases.
- Potential for patent opposition based on prior disclosures of similar compounds.
- Risk of invalidation if claimed compounds are found in earlier literature or patents.
Summary
U.S. Patent 10,772,883 covers a broad class of heterocyclic compounds with specific substitutions, claiming their use in treating cancers and inflammatory diseases, formulations, and combination therapies. While it aims for broad protection, its scope interacts with extensive prior art. The landscape features active innovation by major pharmaceutical firms concentrating on kinase inhibitors and derivatives.
Key Takeaways
- The patent's claims focus on specific heterocyclic compounds and their therapeutic applications.
- It encompasses compounds, formulations, and treatment methods.
- The patent landscape is crowded with similar kinase inhibitor patents, indicating a competitive space.
- Validity depends on navigating prior art related to heterocyclic chemistry and therapeutic use.
- Broad claims may face challenges, requiring strategic patent prosecution and lifecycle management.
FAQs
1. Can the patent be challenged based on prior art?
Yes. Similar heterocyclic compounds and methods could serve as prior art, potentially impacting the patent's validity.
2. Does the patent cover all possible substitutions on the core compound?
No. It specifies certain substitutions; modifications outside those claims may fall outside scope.
3. What diseases are targeted by the claims?
Primarily cancers and inflammatory or autoimmune conditions.
4. Can competitors develop similar compounds?
Potentially, if they modify the structure to avoid infringement and do not infringe on the specific claims.
5. How does this patent compare to international patents?
It closely mirrors global filings in the kinase inhibitor space, with many similar patents in Europe, China, and Japan.
References
[1] U.S. Patent and Trademark Office. (2020). Patent No. 10,772,883.
[2] World Intellectual Property Organization. (2022). Patent landscape reports on kinase inhibitors.
[3] European Patent Office. (2021). Patent filings related to heterocyclic anticancer compounds.
